What is Glaukos Corp?
Glaukos Corporation is a prominent ophthalmic pharmaceutical and medical technology company dedicated to pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company is recognized for its iStent and iStent inject W micro-bypass stents, designed to improve aqueous humor outflow during cataract surgery for mild-to-moderate open-angle glaucoma. Glaukos's robust pipeline includes iStent Infinite for advanced glaucoma cases and iDose TR, an intracameral procedural pharmaceutical therapy aimed at reducing intraocular pressure. The company distributes its innovative products through a direct sales force and international distributors, reflecting its global reach and commitment to advancing eye care solutions.
How much funding has Glaukos Corp raised?
Glaukos Corp has raised a total of $187.3M across 4 funding rounds:
Series A
$10M
Series D
$35M
Series F
$30M
Stock Offering
$112.3M
Series A (2002): $10M with participation from Domain Associates, Frazier Healthcare Partners, and Versant Ventures
Series D (2008): $35M led by Fjord Ventures, Domain Associates, OrbiMed, Frazier Healthcare Partners, Montreux Equity Partners, Versant Ventures, and InterWest Partners
Series F (2013): $30M supported by Domain Associates, OrbiMed, Frazier Healthcare Partners, Montreux Equity Partners, Versant Ventures, InterWest Partners, and Meritech
Stock Issuance/Offering (2015): $112.3M, investors not publicly disclosed
Key Investors in Glaukos Corp
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments. It manages nine subsequent biotech venture capital funds and has a total of $2.8 billion in assets. The firm has provided VC funding to 194 biopharmaceutical, device, and diagnostic companies, resulting in 90 IPOs and 110 M&A events, with a combined market cap of $190 billion for the funded companies. Its intended clients include biotech startups and investors looking to enter the biotech sector.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services, bringing together investment professionals with extensive experience in life sciences and healthcare business development.
Frazier Healthcare Partners
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders.
What's next for Glaukos Corp?
With substantial enterprise-level backing, Glaukos Corp. is strategically positioned for accelerated growth and continued innovation in the competitive ophthalmic market. The significant capital infusion, particularly the recent strategic investment, will likely fuel further research and development of its promising pipeline, including iDose TR and iStent Infinite. Expansion of its commercial operations, both domestically and internationally, is anticipated as the company seeks to broaden market penetration for its existing stent technologies and upcoming therapies. This sustained financial support enables Glaukos to pursue its mission of transforming the treatment landscape for debilitating eye conditions, potentially leading to further market leadership and value creation.
See full Glaukos Corp company page
